Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9687982 | 0.79 | PTPN1 (0.36) | PTPN1CDC25BLMNA | |
| SCHEMBL5048212 | 0.79 | SIRT2 (0.35) | PTPN1CDC25B | |
| SCHEMBL16174854 | 0.75 | LMNA (0.44) | PTPN1CDC25BLMNA | |
| SCHEMBL16174752 | 0.75 | PTPN1 (0.36) | PTPN1CDC25BLMNA | |
| SCHEMBL16175080 | 0.73 | PTPN1 (0.35) | PTPN1CDC25BLMNA | |
| SCHEMBL892475 | 0.72 | TSHR (0.39) | PTPN1LMNA | |
| SCHEMBL28578899 | 0.71 | HSD11B1 (0.32) | PTPN1CDC25BLMNA | |
| SCHEMBL2710911 | 0.70 | PTPN1 (0.40) | PTPN1CDC25BLMNA | |
| SCHEMBL30583030 | 0.68 | PTPN1 (0.35) | PTPN1CDC25BLMNA | |
| SCHEMBL11188189 | 0.67 | SIRT2 (0.39) | PTPN1CDC25BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627631-B1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-8895535-B2 | Pyrrolidinones as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20130296274-A1 | PYRROLIDINONES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
| EP-2627631-A1 | PYRROLIDINONES AS METAP2 INHIBITORS | Merck Patent GmbH (DE) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012048775-A1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2012-04-19 | — | — | WO | disclosed |
| EP-0486807-A1 | Process for preparing 5-aroyl-2,3-dihydro-1H-pyrrolizine-1,1-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1992-05-27 | — | — | EP | disclosed |
| US-5082951-A | Process for preparing 5-aroyl-2,3-dihydro-1H-pyrrolizine-1,1-dicarboxylates (I) and intermediates therefor | SYNTEX (U.S.A.) INC. (US) | 1992-01-21 | — | — | US | disclosed |
| US-4988822-A | Intermediates for preparing 5-aroyl-1,2-dihydro-3H-pyrrolo(1,2-A)pyrrole-1,1-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1991-01-29 | — | — | US | disclosed |
| US-4873340-A | Process for preparing 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-A]pyrrole-1,1-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296274-A1 | PYRROLIDINONES AS METAP-2 INHIBITORS | METAP1, METAP2, DNPEP | PTPN1 1395/4885CDC25B 298/4885LMNA 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.